TCRT is currently developing the following drugs: Ad-Rts-Hil-12, Veledimex, Cemiplimab-Rwlc, Ad-Rts-Hil-12, Veledimex, Nivolumab, Ad-Rts-Hil-12, Veledimex. These drug candidates are in various stages of clinical development as the company works toward FDA approval.